Huprines for Alzheimer's disease drug development

Author： Muñoz-Torrero Diego   Camps Pelayo  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.3, Iss.1, 2008-01, pp. : 65-81

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Treatments in Development for Alzheimer's Disease

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 42, Iss. 1, 2012-03 ,pp. : 58-65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tacrine-Huperzine A Hybrids (Huprines) A New Class of Highly Potent and Selective Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 1, Iss. 2, 2001-07 ,pp. : 163-174

Bentham Science Publishers

Access to resources Recommend Favorite

&ggr;-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 12, 2011-06 ,pp. : 1513-1527

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease

By  

Current Medicinal Chemistry, Vol. 22, Iss. 3, 2015-01 ,pp. : 373-404

Bentham Science Publishers

Access to resources Recommend Favorite

Vaccine Development for Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 12, Iss. 33, 2006-11 ,pp. : 4283-4293

Bentham Science Publishers

Access to resources Recommend Favorite